slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 66,871-66,900
Pages 3,679
Rows per page 30
Component
66,871-66,900 of 110,355
10
The slide shows a downward trend in efficiency ratio (positive) and a fluctuating trend in equity/assets.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · NeedLoop · Logic Chain1 hit
11
The slide displays two line charts tracking financial performance over time.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · NeedLoop · Logic Chain1 hit
12
The slide highlights financial performance metrics for MainStreet Bancshares, Inc. with specific footnotes regarding non-GAAP measures and valuation divergence.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · NeedLoop · Logic Chain1 hit
13
The chart uses a combination of a bar chart for asset values and a line chart with callout nodes for historical events.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · Satisfaction1 hit
14
The slide highlights a 38% CAGR for DDA and notes that core deposits make up 71% of the total.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · Satisfaction1 hit
16
The CAGR is calculated for the period 2015-2021.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · Satisfaction1 hit
18
Includes a table of credit quality ratios and non-performing assets, a bar chart of loss reserves, and two line charts showing NPAs/Assets and ALLL/Gross Loans.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · Satisfaction1 hit
19
The slide highlights the cost and structure of subordinated debt as a component of the holding company's capital stack.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · Satisfaction1 hit
30
Includes a sentiment analysis gauge showing a 'Buy' rating.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · Action1 hit
04
The slide illustrates the self-assembly of Phosphatidylserine (PS) and Calcium ions into a cochleate structure.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
14
The slide details the dosing regimens for different cohorts over induction and consolidation phases.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
16
The chart uses a vertical dotted line at 0.2 to denote a clinical efficacy threshold.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Traction1 hit
21
The slide uses a chevron-based timeline to illustrate the lifecycle management strategy.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
04
The slide presents preliminary financial data for the third quarter of 2022, including income statement components and key balance sheet items.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations 1 hit
06
The chart compares quarterly container volumes between 2021 and 2022.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations 1 hit
07
The chart shows a 15.1% decrease in Q3 2022 volume compared to Q3 2021.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations 1 hit
09
Includes a footnote regarding 4Q21 volume benefit from a 53rd week.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations 1 hit
10
The chart shows quarterly operating income for 2021 and 2022, with Q3 2022 highlighted as a range.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations 1 hit
04
The slide details a strategic partnership involving equity investment and asset licensing.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
05
Includes details on upfront payments, private placement, and milestone/royalty structures.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
07
NASH (Non-Alcoholic Steatohepatitis); IND (Investigational New Drug); MAD (Multiple Ascending Dose); SAD (Single Ascending Dose).NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
08
The slide serves as a title or introductory page for a specific drug candidate.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
09
Includes definitions of acronyms and citations for preclinical studies.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
10
Study methodology involves 10-week treatment on high fat/fructose/CHO diet.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
11
Study design timeline included; statistical significance noted for treatment groups.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
12
Includes definitions for abbreviations and source citations.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
13
NASH (Non-Alcoholic Steatohepatitis); NAFLD (Non-Alcoholic Fatty Liver Disease); T2DM (Type 2 Diabetes Mellitus); FPFV (First Patient First Visit); LPLV (Last Patient Last Visit).NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
15
The slide uses a hub-and-spoke diagram to illustrate the systemic effects of oxyntomodulin.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
16
Data from preclinical study in HF-DIO mice.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
17
The slide highlights that DA-1726 efficacy is likely due to dual GLP1R/GCGR agonism.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit